Empyrean Systems

Empyrean Systems is a pharmaceutical manufacturer and biotechnology research corporation based in Kunari City, with its headquarters in the Kunari City Business District. It is the leading producer of most medical-grade pharmaceuticals and medications in Kunari City, with its products accounting for over 80% of all prescribed and over-the-counter medications in Kunari City.
As of May of 2101, Empyrean Systems employs over 100,000 people.

Structure

Empyrean Systems is owned primarily by two shareholders, Gary Novak and Marc Simmons, with the two men owning over 80% of shares between them. The other 20% of shares are largely distributed between wealthy aristocratic investors and public shareholders. The current CEO is Kyle Crowe, a businessman who's been in management positions in VorTECH, NSRx, and Vulcan.

History

Empyrean Systems was founded by venture capitalists Robert Aldrich and Gene Novak in 2052 - both of whom were seeking to fund medical research on improving physical and mental functions. Aldrich and Novak partnered with Balthazar Simmons, a leading biochemist and cyberware expert responsible for many of the leading technologies in cybernetic muscle and bone enhancements at the time. Initially, the company began with research in the fields of anatomy and altering the nature of proteins and enzymes within the body - before shifting to a greater focus on chemical research and magical augments.
By 2060, Empyrean Systems became a dominant force in the pharmaceutical field, acquiring various smaller manufacturers and monopolizing the production of many common drugs and supplements. Their success continued as they began to uncover new ways to alter chemical reactions with magical augmentation - allowing for the production of stronger, superior medications and supplements.
In 2089, Empyrean Systems released a series of supplements meant to increase tenacity and longevity in combat. Months later, the Inner-City Wars broke out, leading to massive profits for Empyrean. They then used these profits to acquire NSRx, a competing pharmaceutical manufacturer - and the developer of Emergen-C.
In 2101, Empyrean Systems acquired VorTECH in a 200 billion GEC deal. They rebranded their newly acquired subsidiary into Sequence - a new research corporation meant to spearhead research into gene-alteration and magical DNA augmentation.

Founding Date

2052

Type

Corporation, Pharmaceutical